Chemical Engineering Seminars - Antibiotic Probiotics Reduce Pathogen Counts in Host GI Tracts
Event details
| Date | 01.06.2016 |
| Hour | 16:15 › 17:15 |
| Speaker | Prof. Yiannis N. Kaznessis |
| Location | |
| Category | Conferences - Seminars |
Foodborne gastrointestinal infections are significant causes of morbidity and mortality worldwide. Alarmingly, often because of the extensive, non-therapeutic use of antibiotics in agriculture, foodborne bacteria are emerging that are resistant to our most potent drugs. We will discuss a new approach to reduce the use of antibiotics in food-producing animals and to treat gastrointestinal infections. We engineer probiotic, lactic acid bacteria (LAB) that express and release antimicrobial peptides (AMPs). LAB are part of the gastrointestinal microflora and can be safely delivered with known benefits to humans and animals. AMPs are proteins that can be readily produced by LAB. One unique aspect of our approach is the use of synthetic promoters that precisely regulate the delivery of AMP molecules.
At the heart of proposed efforts are multiscale models that guide explanations and predictions of the antagonistic activity of recombinant LAB against pathogenic strains. Models are developed to quantify how AMPs kill bacteria at distinct but tied scales. Using atomistic simulations the various interaction steps between peptides and cell membranes are explored. Mesoscopic models are developed to study ion transport and depolarization of membranes treated with AMPs. Stochastic kinetic models are developed to quantify the strength of synthetic promoters and AMPs expression.
Experimentally, we engineer lactic acid bacteria to inducibly produce antimicrobial peptides. We have developed a library of synthetic biological constructs. We test modified bacteria against pathogenic bacteria. We will present in vitro results against salmonella and enterococcus. We will also present proof-of-concept results of in vivo studies with turkey poults and mice.
At the heart of proposed efforts are multiscale models that guide explanations and predictions of the antagonistic activity of recombinant LAB against pathogenic strains. Models are developed to quantify how AMPs kill bacteria at distinct but tied scales. Using atomistic simulations the various interaction steps between peptides and cell membranes are explored. Mesoscopic models are developed to study ion transport and depolarization of membranes treated with AMPs. Stochastic kinetic models are developed to quantify the strength of synthetic promoters and AMPs expression.
Experimentally, we engineer lactic acid bacteria to inducibly produce antimicrobial peptides. We have developed a library of synthetic biological constructs. We test modified bacteria against pathogenic bacteria. We will present in vitro results against salmonella and enterococcus. We will also present proof-of-concept results of in vivo studies with turkey poults and mice.
Practical information
- General public
- Free